17:27 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea and...
18:21 , Oct 8, 2018 |  BC Extra  |  Company News

Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued Monday for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
18:10 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Acacia raises €40M in IPO

Acacia Pharma Group plc (Euronext:ACPH) raised €40 million ($49.3 million) on March 2 through the sale of 11.1 million shares at €3.60 in an IPO underwritten by Bank Degroof Petercam NV/SA and RBC Europe. The...
20:14 , Mar 2, 2018 |  BC Extra  |  Financial News

Acacia raises €40M in IPO

Acacia Pharma Group plc (Euronext:ACPH) raised €40 million ($49.3 million) through the sale of 11.1 million shares at €3.60 in an IPO underwritten by Bank Degroof Petercam NV/SA and RBC Europe. The price values the...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
17:38 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Acacia's PONV therapy

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting (PONV)....
08:03 , Jan 4, 2018 |  BC Extra  |  Company News

FDA reviewing Acacia's PONV therapy

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting. The...
23:25 , Nov 15, 2017 |  BC Extra  |  Company News

Management tracks: Outpost, Torque

Genitourinary play Outpost Medicine LLC (Indianapolis, Ind.) named Scott Byrd president and CEO. He succeeds interim CEO David Socks, who will remain on the company's board. Byrd was president and COO at the Acacia Pharma...